Tech Company Financing Transactions
Taligen Therapeutics Funding Round
Taligen Therapeutics closed a $26 million venture capital round on 5/12/2009. Investors included Alta Partners, Clarus and Sanderling Ventures.
Transaction Overview
Company Name
Announced On
5/12/2009
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12635 East Montview Blvd 223
Aurora, CO 80045
USA
Aurora, CO 80045
USA
Phone
Website
Email Address
Overview
Taligen's lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Abbie Celniker
Chief Scientific Officer
Michael Holers
President
Woodruff Emlen
Browse more venture capital transactions:
Prev: 5/12/2009: Myvu venture capital transaction
Next: 5/12/2009: PlexPress venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs